Free Republic

A widely-used diabetes drug should be pulled from the market, European regulators say.Avandia is used to control blood sugar levels in type 2 diabetes patients. It was licensed 10 years ago and more than 100,000 patients in the UK use it despite on-going concerns linking it to heart problems. After reviewing safety data, the European Medicines Agency said the benefits no longer outweighed the risks and it should be suspended. The drug - generic name rosiglitazone - is also used in combination with other drugs under the names Avandamet and Avaglim.

Hundreds of people taking Avandia, a controversial diabetes medicine, needlessly suffer heart attacks and heart failure each month, according to confidential government reports that recommend the drug be removed from the market. The reports, obtained by The New York Times, say that if every diabetic now taking Avandia were instead given a similar pill named Actos, about 500 heart attacks and 300 cases of heart failure would be averted every month because Avandia can hurt the heart. Avandia, intended to treat Type 2 diabetes, is known as rosiglitazone and was linked to 304 deaths during the third quarter of 2009....

A molecular pathway could explain how a class of drugs leads to heart failure. Researchers who study how tumours balloon in size have discovered one way that enlargement of the heart can lead to heart failure. The work, although mostly done in mice, could help explain why a class of diabetes drugs called thiazolidinediones (TZDs) increase the risk of heart failure.These drugs have been controversial since a 2007 analysis1 of Avandia (rosiglitazone), a TZD made by GlaxoSmithKline, suggested that patients taking it are at increased risk of heart attack. Less controversial are data linking TZDs with heart failure, a distinct...

A large clinical study meant to test the heart safety of the diabetes treatment Avandia may be in jeopardy as a result of recent reports of the drug’s risks, according to an executive at its maker, GlaxoSmithKline. Dr. Ronald L. Krall, the medical director for GlaxoSmithKline, said in a telephone interview yesterday that some of the 4,450 patients enrolled in the drug trial, called Record, have dropped out this week because of safety concerns about Avandia. Dr. Krall said he did not yet know how many patients have withdrawn, but said Glaxo was now worried about whether it could complete...

ASSOCIATED PRESS The largest diabetes prevention study ever done has found that a drug already used to treat the disease also can help keep "pre-diabetics" from developing it. But many experts say losing weight and exercising remain a safer, cheaper approach. The drug, rosiglitazone, or Avandia, appeared to cut the risk of developing Type 2 diabetes by more than half, doctors reported Friday. Type 2 is the most common form of diabetes, afflicting more than 200 million people worldwide. Avandia also helped restore normal blood-sugar function in many of those who took it. A second part of the study found...